In this comprehensive pharmacogenetic study among 3,729 premenopausal women with breast cancer, genetic variants involved in phase I metabolism, particularly among CYP2D6 genes, were associated with early tamoxifen discontinuation. Here, CYP2D6 is linked to breast carcinoma.